- $135.55m
- $118.16m
- $27.47m
U.S. RESEARCH ROUNDUP- Pioneer Natural Resources,Oxford Industries, Nutrien
Cue Biopharma Inc reports results for the quarter ended in June - Earnings Summary
Brief: Cue Biopharma, Inc. Q2 collaboration revenue USD 1.382 million
Cue Biopharma Inc expected to post a loss of 30 cents a share - Earnings Preview
Brief: Cue Biopharma Presents Positive Data Update From Ongoing Phase 1 Trials Of Cue-101 For Recurrent/Metastatic Hpv+ Head And Neck Squamous Cell Carcinoma At The 2023 American Society Of Clinical Oncology Annual Meeting
Cue Biopharma Inc reports results for the quarter ended in March - Earnings Summary
Brief: Cue Biopharma Inc Files For Mixed Shelf Offering Of Up To $300 Mln
Brief: Cue Biopharma Reports First Quarter 2023 Financial Results
Cue Biopharma Inc expected to post a loss of 29 cents a share - Earnings Preview
Brief: Cue Biopharma Appoints Patrick Verheyen To Its Board Of Directors
Cue Biopharma Inc reports results for the quarter ended in December - Earnings Summary
Brief: Cue Biopharma Reports Fourth Quarter Results
Cue Biopharma Inc expected to post a loss of 31 cents a share - Earnings Preview
Brief: Cue Biopharma Enters Into A Strategic Collaboration With Ono Pharmaceutical For Cue-401
Brief: Cue Biopharma Announces Chief Medical Officer Transition
Brief: Cue Biopharma Inc Files Prospectus Relates To Resale From Time To Time Of Up To 18.4 Million Shares Of Common Stock By Selling Stockholders - Filing
Cue Biopharma Inc reports results for the quarter ended in September - Earnings Summary
Brief: Cue Biopharma Reports Third Quarter 2022 Financial Results
Cue Biopharma Inc expected to post a loss of 38 cents a share - Earnings Preview